{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=aflibercept+2+mg&page=2",
    "query": {
      "intervention": "aflibercept 2 mg",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 121,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=aflibercept+2+mg&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=aflibercept+2+mg&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T13:41:46.731Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00794417",
      "title": "A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Carcinoma",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2008-11-30",
      "completion_date": "2011-06-30",
      "has_results": true,
      "last_update_posted_date": "2020-12-10",
      "last_synced_at": "2026-10-02T13:41:46.731Z",
      "location_count": 14,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Stanford, California + 11 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Hines",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00794417"
    },
    {
      "nct_id": "NCT00789477",
      "title": "DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Laser Photocoagulation",
          "type": "PROCEDURE"
        },
        {
          "name": "Intravitreal Aflibercept Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 221,
      "start_date": "2008-12",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2014-09-09",
      "last_synced_at": "2026-10-02T13:41:46.731Z",
      "location_count": 42,
      "location_summary": "Artesia, California • Beverly Hills, California • Mountain View, California + 38 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00789477"
    },
    {
      "nct_id": "NCT00574275",
      "title": "Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Neoplasm"
      ],
      "interventions": [
        {
          "name": "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 546,
      "start_date": "2007-12",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2016-06-07",
      "last_synced_at": "2026-10-02T13:41:46.731Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574275"
    },
    {
      "nct_id": "NCT02712008",
      "title": "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "REGN910-3",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal Aflibercept Injection (IAI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2016-03-02",
      "completion_date": "2017-07-10",
      "has_results": true,
      "last_update_posted_date": "2018-10-03",
      "last_synced_at": "2026-10-02T13:41:46.731Z",
      "location_count": 51,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Arcadia, California + 48 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02712008"
    },
    {
      "nct_id": "NCT02713204",
      "title": "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "REGN910-3",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal Aflibercept Injection (IAI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 365,
      "start_date": "2016-03-31",
      "completion_date": "2017-10-03",
      "has_results": true,
      "last_update_posted_date": "2019-05-07",
      "last_synced_at": "2026-10-02T13:41:46.731Z",
      "location_count": 87,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02713204"
    },
    {
      "nct_id": "NCT03126786",
      "title": "Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "IVT aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham SC",
          "type": "DRUG"
        },
        {
          "name": "SC CLS-TA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clearside Biomedical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2017-07-11",
      "completion_date": "2018-04-17",
      "has_results": true,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-10-02T13:41:46.731Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03126786"
    },
    {
      "nct_id": "NCT00396591",
      "title": "AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2006-10",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2013-01-10",
      "last_synced_at": "2026-10-02T13:41:46.731Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00396591"
    },
    {
      "nct_id": "NCT04450329",
      "title": "A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "SB15 (Proposed aflibercept biosimilar)",
          "type": "DRUG"
        },
        {
          "name": "Eylea (Aflibercept)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Samsung Bioepis Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 449,
      "start_date": "2020-06-23",
      "completion_date": "2022-03-16",
      "has_results": true,
      "last_update_posted_date": "2024-02-05",
      "last_synced_at": "2026-10-02T13:41:46.731Z",
      "location_count": 3,
      "location_summary": "Colorado Springs, Colorado • Chevy Chase, Maryland • Abilene, Texas",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        },
        {
          "city": "Abilene",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04450329"
    },
    {
      "nct_id": "NCT01579760",
      "title": "Intravitreal Aflibercept Injection for Radiation Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Radiation Retinopathy",
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "Aflibercept every 2 months",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept monthly",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2012-11",
      "completion_date": "2019-03-27",
      "has_results": false,
      "last_update_posted_date": "2019-04-25",
      "last_synced_at": "2026-10-02T13:41:46.731Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Houston, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01579760"
    },
    {
      "nct_id": "NCT01543568",
      "title": "Study for Recalcitrant Age Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "aflibercept 2.0 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David M. Brown, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2012-02",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2017-01-02",
      "last_synced_at": "2026-10-02T13:41:46.731Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01543568"
    }
  ]
}